

Paul J Martin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1940989/publications.pdf>

Version: 2024-02-01

177
papers

24,519
citations

9756

73
h-index

7333

152
g-index

177
all docs

177
docs citations

177
times ranked

15822
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 945-956. | 2.0 | 3,213 |
| 2 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 389-401.e1. | 2.0 | 2,636 |
| 3 | Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2010, 363, 2091-2101. | 13.9 | 1,335 |
| 4 | Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. <i>Nature Genetics</i> , 2010, 42, 508-514. | 9.4 | 1,132 |
| 5 | Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. <i>Blood</i> , 2011, 117, 3214-3219. | 0.6 | 544 |
| 6 | Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. <i>Blood</i> , 2003, 102, 756-762. | 0.6 | 531 |
| 7 | Endothelial Cells of Hematopoietic Origin Make a Significant Contribution to Adult Blood Vessel Formation. <i>Circulation Research</i> , 2000, 87, 728-730. | 2.0 | 507 |
| 8 | First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1150-1163. | 2.0 | 506 |
| 9 | Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 252-266. | 2.0 | 445 |
| 10 | Optimizing Outcome After Unrelated Marrow Transplantation by Comprehensive Matching of HLA Class I and II Alleles in the Donor and Recipient. <i>Blood</i> , 1998, 92, 3515-3520. | 0.6 | 442 |
| 11 | Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 31-47. | 2.0 | 427 |
| 12 | Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. <i>Blood</i> , 2002, 100, 415-419. | 0.6 | 403 |
| 13 | Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 3249-3256. | 0.8 | 361 |
| 14 | Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. <i>Blood</i> , 1997, 89, 4226-4235. | 0.6 | 358 |
| 15 | The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 211-234. | 2.0 | 328 |
| 16 | Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. <i>Human Immunology</i> , 1990, 29, 79-91. | 1.2 | 325 |
| 17 | Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2010, 28, 1011-1016. | 0.8 | 321 |
| 18 | Ancillary Therapy and Supportive Care of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 375-396. | 2.0 | 316 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 984-999. | 2.0 | 293 |
| 20 | How we treat chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 606-615. | 0.6 | 275 |
| 21 | Duration of immunosuppressive treatment for chronic graft-versus-host disease. <i>Blood</i> , 2004, 104, 3501-3506. | 0.6 | 269 |
| 22 | Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. <i>Blood</i> , 2002, 100, 48-51. | 0.6 | 263 |
| 23 | Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-CD25 Lymphocyte Globulin to Assess Impact on Chronic Graft-versus-Host Disease-free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4011. | 0.8 | 258 |
| 24 | Involvement of the B-lymphoid system in chronic myelogenous leukaemia. <i>Nature</i> , 1980, 287, 49-50. | 13.7 | 237 |
| 25 | Airflow Obstruction after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 208-214. | 2.5 | 233 |
| 26 | NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 589-603. | 2.0 | 228 |
| 27 | Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. <i>Blood</i> , 2009, 114, 702-708. | 0.6 | 218 |
| 28 | Graft-versus-Host Disease and Graft-versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1530-1538. | 0.8 | 197 |
| 29 | Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. <i>Blood</i> , 2011, 118, 4242-4249. | 0.6 | 196 |
| 30 | A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 761-767. | 2.0 | 195 |
| 31 | Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. <i>Blood</i> , 2003, 102, 820-826. | 0.6 | 190 |
| 32 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1167-1187. | 2.0 | 182 |
| 33 | Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. <i>Blood</i> , 2016, 127, 1502-1508. | 0.6 | 174 |
| 34 | A phase I/II trial of iodine-131-anti-CD20 (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , 2000, 96, 2934-2942. | 0.6 | 173 |
| 35 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 491-505. | 2.0 | 165 |
| 36 | Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. <i>Annals of Internal Medicine</i> , 2020, 172, 229. | 2.0 | 157 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 710-716. | 2.0 | 151 |
| 38 | Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2009, 113, 5074-5082. | 0.6 | 143 |
| 39 | Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 320-327. | 2.0 | 142 |
| 40 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 780-792. | 2.0 | 124 |
| 41 | Thalidomide for treatment of patients with chronic graft-versus-host disease. <i>Blood</i> , 2000, 96, 3995-3996. | 0.6 | 122 |
| 42 | Correlation Between Disparity for the Minor Histocompatibility Antigen HA-1 and the Development of Acute Graft-Versus-Host Disease After Allogeneic Marrow Transplantation. <i>Blood</i> , 1999, 94, 2911-2914. | 0.6 | 121 |
| 43 | Biomarker Panel for Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 2583-2590. | 0.8 | 118 |
| 44 | Use of Fluid-Ventilated, Gas-Permeable Scleral Lens for Management of Severe Keratoconjunctivitis Sicca Secondary to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1016-1021. | 2.0 | 115 |
| 45 | Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. <i>Blood</i> , 2009, 113, 2888-2894. | 0.6 | 115 |
| 46 | Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 449-455. | 2.0 | 113 |
| 47 | An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. <i>Blood</i> , 2006, 108, 749-755. | 0.6 | 112 |
| 48 | Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. <i>Blood</i> , 2015, 126, 113-120. | 0.6 | 110 |
| 49 | Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. <i>Blood</i> , 2017, 129, 791-798. | 0.6 | 109 |
| 50 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1343-1359. | 2.0 | 105 |
| 51 | Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. <i>Blood</i> , 2012, 120, 2545-2552. | 0.6 | 101 |
| 52 | Hematopoietic stem cell transplants from unrelated donors. <i>Immunological Reviews</i> , 1997, 157, 141-151. | 2.8 | 99 |
| 53 | Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 384-387. | 2.0 | 98 |
| 54 | Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. <i>British Journal of Haematology</i> , 1989, 72, 567-572. | 1.2 | 95 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 835-844. | 2.0 | 95 |
| 56 | Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. <i>Blood</i> , 2014, 123, 786-793. | 0.6 | 94 |
| 57 | Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 5098-5103. | 0.6 | 93 |
| 58 | Evaluation of published single nucleotide polymorphisms associated with acute GVHD. <i>Blood</i> , 2012, 119, 5311-5319. | 0.6 | 92 |
| 59 | Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. <i>Blood</i> , 2014, 124, 3221-3227. | 0.6 | 92 |
| 60 | Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. <i>Nature Genetics</i> , 2009, 41, 1341-1344. | 9.4 | 91 |
| 61 | Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 573-584. | 2.0 | 88 |
| 62 | PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. <i>Journal of Clinical Investigation</i> , 2017, 127, 1960-1977. | 3.9 | 88 |
| 63 | Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2014, 124, 1363-1371. | 0.6 | 86 |
| 64 | Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. <i>Blood</i> , 2012, 120, 2796-2806. | 0.6 | 84 |
| 65 | Late Cardiovascular Complications after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 794-800. | 2.0 | 84 |
| 66 | Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e409-e418. | 2.2 | 84 |
| 67 | Validation of Measurement Scales in Ocular Graft-versus-Host Disease. <i>Ophthalmology</i> , 2012, 119, 487-493. | 2.5 | 83 |
| 68 | Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. <i>Blood</i> , 2014, 124, 287-295. | 0.6 | 83 |
| 69 | Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. <i>Blood</i> , 2016, 127, 3082-3091. | 0.6 | 83 |
| 70 | Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation. <i>Blood</i> , 2017, 129, 2693-2701. | 0.6 | 80 |
| 71 | Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. <i>Haematologica</i> , 2012, 97, 451-458. | 1.7 | 77 |
| 72 | A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1323-1330. | 2.0 | 76 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 337-344. | 2.0 | 76 |
| 74 | Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2011, 118, 456-463. | 0.6 | 75 |
| 75 | Treatment of chronic graft-versus-host disease: Past, present and future. <i>The Korean Journal of Hematology</i> , 2011, 46, 153. | 0.7 | 74 |
| 76 | Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. <i>Blood</i> , 2016, 127, 2249-2260. | 0.6 | 74 |
| 77 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 545-557. | 0.6 | 72 |
| 78 | A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2016, 22, 319-327. | 3.2 | 68 |
| 79 | Role of CD28 in Acute Graft-Versus-Host Disease. <i>Blood</i> , 1998, 92, 2963-2970. | 0.6 | 62 |
| 80 | Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 777-784. | 2.0 | 62 |
| 81 | Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1418-1424. | 2.0 | 62 |
| 82 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 817-835. | 0.6 | 62 |
| 83 | A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus-Host Disease (cGVHD) Therapeutic Response Measures: Feasibility, Interrater Reliability, and Minimum Detectable Change. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1619-1629. | 2.0 | 61 |
| 84 | HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1382-1387. | 2.0 | 60 |
| 85 | Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1594-1601. | 2.0 | 60 |
| 86 | Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. <i>Nature Communications</i> , 2017, 8, 978. | 5.8 | 58 |
| 87 | Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 2340-2346. | 0.6 | 55 |
| 88 | Secondary Treatment of Acute Graft-versus-Host Disease: A Critical Review. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 982-988. | 2.0 | 52 |
| 89 | An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 360-367. | 0.6 | 52 |
| 90 | Assessment of Joint and Fascia Manifestations in Chronic Graft-versus-Host Disease. <i>Arthritis and Rheumatology</i> , 2014, 66, 1044-1052. | 2.9 | 50 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 555-562. | 2.0 | 50 |
| 92 | Homotypic aggregation of human cell lines by HLA class II-, class Ia- and HLA-G-specific monoclonal antibodies. <i>European Journal of Immunology</i> , 1991, 21, 2121-2131. | 1.6 | 49 |
| 93 | Molecular diversity of the HLA-D locus in unrelated marrow transplantation. <i>Tissue Antigens</i> , 1994, 44, 93-99. | 1.0 | 49 |
| 94 | Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1380-1384. | 2.0 | 49 |
| 95 | Biology of Chronic Graft-versus-Host Disease: Implications for a Future Therapeutic Approach. <i>Keio Journal of Medicine</i> , 2008, 57, 177-183. | 0.5 | 49 |
| 96 | Clinical Benefit of Response in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1517-1524. | 2.0 | 47 |
| 97 | How I treat steroid-refractory acute graft-versus-host disease. <i>Blood</i> , 2020, 135, 1630-1638. | 0.6 | 46 |
| 98 | Multi-centre validation of the prognostic value of the haematopoietic cell transplantation-specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2015, 170, 574-583. | 1.2 | 45 |
| 99 | Polymorphism of HLA-DRA-associated DRB1 genes as defined by sequence-specific oligonucleotide probe hybridization and sequencing. <i>Tissue Antigens</i> , 1991, 38, 169-177. | 1.0 | 44 |
| 100 | Signal transduction by HLA class II antigens expressed on activated T cells. <i>European Journal of Immunology</i> , 1991, 21, 123-129. | 1.6 | 44 |
| 101 | Outcomes of Lung Transplantation after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1169-1175. | 2.0 | 43 |
| 102 | Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. <i>Blood</i> , 2016, 127, 160-166. | 0.6 | 43 |
| 103 | Bandage Soft Contact Lenses for Ocular Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2002-2007. | 2.0 | 41 |
| 104 | Reevaluation of the Pretransplant Assessment of Mortality Score after Allogeneic Hematopoietic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 848-854. | 2.0 | 40 |
| 105 | Association of Plasma CD163 Concentration with De Novo Onset Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1250-1256. | 2.0 | 38 |
| 106 | Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1679-1686. | 2.0 | 37 |
| 107 | Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2022, 40, 1174-1185. | 0.8 | 36 |
| 108 | A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. <i>British Journal of Haematology</i> , 1992, 80, 49-54. | 1.2 | 35 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. <i>Blood</i> , 2020, 136, 1903-1906. | 0.6 | 34 |
| 110 | Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1094-1101. | 2.0 | 33 |
| 111 | Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. <i>Blood</i> , 2016, 128, 2450-2456. | 0.6 | 32 |
| 112 | Prognostic Utility of Routine Chimerism Testing at 2 to 6 Months after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 352-359. | 2.0 | 29 |
| 113 | Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2014, 99, 1618-1623. | 1.7 | 29 |
| 114 | Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2015, 100, 690-695. | 1.7 | 29 |
| 115 | Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1257-1263. | 2.0 | 29 |
| 116 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 729-737. | 0.6 | 29 |
| 117 | Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80. <i>Frontiers in Immunology</i> , 2018, 9, 3061. | 2.2 | 28 |
| 118 | Allogeneic Hematopoietic Cell Transplantation following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 792-798. | 2.0 | 27 |
| 119 | Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 124-132. | 2.0 | 26 |
| 120 | Evaluation of Thalidomide for Treatment or Prevention of Chronic Graft-versus-host Disease. <i>Leukemia and Lymphoma</i> , 2003, 44, 1141-1146. | 0.6 | 25 |
| 121 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466. | 0.6 | 24 |
| 122 | Adherence of adoptively transferred alloreactive Th1 cells in lung: partial dependence on LFA-1 and ICAM-1. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2000, 279, L583-L591. | 1.3 | 23 |
| 123 | Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease. <i>Haematologica</i> , 2014, 99, 385-391. | 1.7 | 23 |
| 124 | Poor Agreement between Clinician Response Ratings and Calculated Response Measures in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1649-1655. | 2.0 | 22 |
| 125 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 632-641. | 0.6 | 21 |
| 126 | National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 10-23. | 2.0 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Recipient and donor genetic variants associated with mortality after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 3224-3233. | 2.5 | 20 |
| 128 | Home Spirometry Telemonitoring for Early Detection of Bronchiolitis Obliterans Syndrome in Patients with Chronic Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 616.e1-616.e6. | 0.6 | 20 |
| 129 | Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 451-458. | 2.0 | 19 |
| 130 | Genetic risk factors for sclerotic graft-versus-host disease. <i>Blood</i> , 2016, 128, 1516-1524. | 0.6 | 18 |
| 131 | Role of the mixed lymphocyte culture (MLC) reaction in marrow donor selection: Matching for transplants from related haploidentical donors. <i>Tissue Antigens</i> , 1994, 44, 83-92. | 1.0 | 17 |
| 132 | Evaluation of Oral Beclomethasone Dipropionate for Prevention of Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 922-929. | 2.0 | 16 |
| 133 | Disability Related to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 772-777. | 2.0 | 16 |
| 134 | MR Imaging Findings in a Neonate With COVID -19-Associated Encephalitis. <i>Pediatric Neurology</i> , 2021, 119, 48-49. | 1.0 | 15 |
| 135 | Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. <i>Blood Advances</i> , 2017, 1, 2247-2256. | 2.5 | 15 |
| 136 | Engagement with INSPIRE, an Online Program for Hematopoietic Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1692-1698. | 2.0 | 14 |
| 137 | Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1424-1431. | 2.0 | 14 |
| 138 | Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 2409-2417. | 2.5 | 14 |
| 139 | IL-22-dependent dysbiosis and mononuclear phagocyte depletion contribute to steroid-resistant gut graft-versus-host disease in mice. <i>Nature Communications</i> , 2021, 12, 805. | 5.8 | 14 |
| 140 | Pitfalls in the Design of Clinical Trials for Prevention or Treatment of Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 31-36. | 2.0 | 13 |
| 141 | Pilot study of lithium to restore intestinal barrier function in severe graft-versus-host disease. <i>PLoS ONE</i> , 2017, 12, e0183284. | 1.1 | 13 |
| 142 | The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 448-451. | 0.6 | 13 |
| 143 | Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. <i>Blood Advances</i> , 2019, 3, 2764-2777. | 2.5 | 12 |
| 144 | Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity. <i>Blood</i> , 2021, 137, 2243-2255. | 0.6 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 145 | Winning the battle of graft versus host. <i>Nature Medicine</i> , 2000, 6, 18-19. | 15.2 | 11 |
| 146 | CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 405-411. | 2.0 | 11 |
| 147 | Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. <i>Blood Advances</i> , 2020, 4, 40-46. | 2.5 | 11 |
| 148 | HLA-DR molecules enhance signal transduction through the CD3/Ti complex in activated T cells. <i>Tissue Antigens</i> , 1991, 38, 72-77. | 1.0 | 10 |
| 149 | HLA-DRB1 frst domain sequences of two new DR11 alleles and one novel DR4 allele. <i>Tissue Antigens</i> , 1993, 42, 533-535. | 1.0 | 9 |
| 150 | Pathogenic neutrophils in acute GVHD. <i>Blood</i> , 2018, 131, 1774-1775. | 0.6 | 9 |
| 151 | Interleukin-23 receptor signaling by interleukin-39 potentiates T cell pathogenicity in acute graft-versus-host disease. <i>American Journal of Transplantation</i> , 2021, 21, 3538-3549. | 2.6 | 9 |
| 152 | Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. <i>Blood Advances</i> , 2021, 5, 4549-4559. | 2.5 | 8 |
| 153 | Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 759.e1-759.e8. | 0.6 | 8 |
| 154 | The positive association of Association for Academic Surgery membership with academic productivity. <i>Journal of Surgical Research</i> , 2016, 205, 163-168. | 0.8 | 7 |
| 155 | Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2021, 138, 1628-1636. | 0.6 | 7 |
| 156 | Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. <i>Leukemia</i> , 2022, 36, 1907-1915. | 3.3 | 7 |
| 157 | Front Line Treatment of Chronic Graft versus Host Disease. , 2009, , 124-133. | | 6 |
| 158 | The impact of members of the Society of University Surgeons on the scholarship of American surgery. <i>Surgery</i> , 2016, 160, 47-53. | 1.0 | 6 |
| 159 | Impact of clinical fellowships on academic productivity in departments of surgery. <i>Surgery</i> , 2016, 160, 1440-1446. | 1.0 | 6 |
| 160 | Sitagliptin to Prevent Acute Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2021, 384, 70-71. | 13.9 | 5 |
| 161 | Murine Models Provide New Insights Into Pathogenesis of Chronic Graft-Versus-Host Disease in Humans. <i>Frontiers in Immunology</i> , 2021, 12, 700857. | 2.2 | 5 |
| 162 | Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplant and investigation into BOS pathogenesis. <i>Transplantation and Cellular Therapy</i> , 2022, , . | 0.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2468-2473. | 2.0 | 4 |
| 164 | A Model of Minor Histocompatibility Antigens in Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 782152. | 2.2 | 4 |
| 165 | Bone marrow transplantation for COVID-like humoral immune deficiency associated with red cell aplasia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1856-1859. | 0.8 | 3 |
| 166 | Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. <i>Blood</i> , 1997, 89, 3880-3887. | 0.6 | 3 |
| 167 | Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin. <i>Bone Marrow Transplantation</i> , 2021, , . | 1.3 | 2 |
| 168 | Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1869-1874. | 2.0 | 1 |
| 169 | Genetic Variants Associated with Inflammatory Bowel Disease and Gut Graft-versus-host Disease. <i>Blood Advances</i> , 2021, 5, 4456-4464. | 2.5 | 1 |
| 170 | Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation. , 0, , 365-375. | | 1 |
| 171 | Rare Variant Genetic Association Study for Transplant-Associated Thrombotic Microangiopathy (TA-TMA) Via Whole Exome Sequencing. <i>Blood</i> , 2021, 138, 745-745. | 0.6 | 1 |
| 172 | Prediction of outcomes after second-line treatment for acute graft-versus-host disease. <i>Blood Advances</i> , 2022, , . | 2.5 | 1 |
| 173 | Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity. <i>Frontiers in Immunology</i> , 2022, 13, . | 2.2 | 1 |
| 174 | Educating Radiologists for Self-governance. <i>Academic Radiology</i> , 2018, 25, 540-542. | 1.3 | 0 |
| 175 | Serious Acute or Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplantation: A Comparison of Myeloablative and Non-Myeloablative Conditioning Regimens.. <i>Blood</i> , 2006, 108, 755-755. | 0.6 | 0 |
| 176 | Genetic Associations with Immune-mediated Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Blood Advances</i> , 2022, , . | 2.5 | 0 |
| 177 | Overview of Hematopoietic Cell Transplantation Immunology. , 0, , 129-144. | | 0 |